Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression

Fernando Magdaleno; Jonel Trebicka

doi:10.1136/gutjnl-2016-313621

Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression

Fernando Magdaleno
, Jonel Trebicka

KI, OUH, Research unit of Medical Gastroenterology (Odense)

University of Chicago
University of Bonn
European Foundation for the Study of Chronic Liver Failure

Research output: Contribution to journal › Comment/debate › Research › peer-review

Original language	English
Journal	Gut
Volume	66
Issue number	9
Pages (from-to)	1540-1541
ISSN	0017-5749
DOIs	https://doi.org/10.1136/gutjnl-2016-313621
Publication status	Published - 1. Sept 2017

Keywords

Extracellular Matrix
Fibrosis
Liver Cirrhosis

Documents & Links

10.1136/gutjnl-2016-313621

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{57c35e272717456499d59f175e3323b7,

title = "Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression",

keywords = "Extracellular Matrix, Fibrosis, Liver Cirrhosis",

author = "Fernando Magdaleno and Jonel Trebicka",

year = "2017",

month = sep,

day = "1",

doi = "10.1136/gutjnl-2016-313621",

language = "English",

volume = "66",

pages = "1540--1541",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "9",

}

TY - JOUR

T1 - Selective LOXL2 inhibition

T2 - potent antifibrotic effects in ongoing fibrosis and fibrosis regression

AU - Magdaleno, Fernando

AU - Trebicka, Jonel

PY - 2017/9/1

Y1 - 2017/9/1

KW - Extracellular Matrix

KW - Fibrosis

KW - Liver Cirrhosis

U2 - 10.1136/gutjnl-2016-313621

DO - 10.1136/gutjnl-2016-313621

M3 - Comment/debate

C2 - 28246311

SN - 0017-5749

VL - 66

SP - 1540

EP - 1541

JO - Gut

JF - Gut

IS - 9

ER -